Adicet Bio (ACET) Projected to Post Quarterly Earnings on Thursday

Adicet Bio (NASDAQ:ACET) is expected to post its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect Adicet Bio to post earnings of ($3.23) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Adicet Bio Stock Performance

Shares of ACET opened at $7.41 on Thursday. Adicet Bio has a 1 year low of $6.41 and a 1 year high of $17.44. The stock has a market capitalization of $70.99 million, a PE ratio of -0.37 and a beta of 1.58. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.62 and a current ratio of 5.62. The stock has a 50-day simple moving average of $7.81 and a 200-day simple moving average of $10.36.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC boosted its holdings in shares of Adicet Bio by 20.0% in the fourth quarter. Squarepoint Ops LLC now owns 55,723 shares of the company’s stock valued at $469,000 after acquiring an additional 9,296 shares during the period. Susquehanna International Group LLP purchased a new stake in Adicet Bio in the 3rd quarter valued at $33,000. Luminus Management LLC acquired a new stake in Adicet Bio during the 4th quarter worth $501,000. Burkehill Global Management LP acquired a new stake in Adicet Bio during the 4th quarter worth $526,000. Finally, Goldman Sachs Group Inc. grew its position in Adicet Bio by 1.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 3,816,556 shares of the company’s stock worth $2,882,000 after purchasing an additional 63,691 shares during the last quarter. Hedge funds and other institutional investors own 83.89% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ACET shares. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target (up from $9.00) on shares of Adicet Bio in a research note on Wednesday, January 21st. Canaccord Genuity Group set a $18.00 target price on shares of Adicet Bio and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adicet Bio in a report on Tuesday, January 27th. Citigroup reiterated a “market perform” rating on shares of Adicet Bio in a report on Wednesday, November 19th. Finally, Wedbush restated an “outperform” rating and set a $80.00 target price on shares of Adicet Bio in a research note on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $69.00.

Adicet Bio Company Profile

Adicet Bio, Inc (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.